Factor influencing tacrolimus blood concentration switching after continuous intravenous infusion to oral administration in allogeneic hematopoietic stem cell transplan recipients with hematological maliganancies

Trial Profile

Factor influencing tacrolimus blood concentration switching after continuous intravenous infusion to oral administration in allogeneic hematopoietic stem cell transplan recipients with hematological maliganancies

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Fluconazole; Itraconazole; Omeprazole; Voriconazole
  • Indications Haematological malignancies
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top